Enhancing QOL in Cancer Patients: An Observational Study on the Incidence and Severity of Platinum-Induced Peripheral Neuropathy at a Single Cancer Centre in Chennai
Abstract
Background and objectives: Chemotherapy-induced peripheral neuropathy (CIPN) is a persistent adverse effect of agents like taxanes, platinum drugs, etc. This study focuses on platinum drugs and aims to compare platinum-based regimens, regarding the incidence and severity of platinum-induced peripheral neuropathy (PIPN), to identify those with higher neurotoxic potential. A secondary objective is to assess patient-specific risk factors to improve analysis accuracy. Methods: A prospective observational study was conducted at a tertiary care hospital, Chennai from September 2024 to February 2025, involving 78 adult cancer patients receiving platinum-based chemotherapy. Stratified sampling ensured equal group representation (n = 26 each). Neuropathy was assessed using NCI-CTCAE criteria, with statistical analysis including chi-square/Fisher’s exact tests and logistic regression. Post hoc analysis identified significant group differences. Results: A total of 18% of participants developed symptoms consistent with peripheral neuropathy (PN). A statistically significant association was observed between platinum-based agents and the occurrence of PN (p = 0.032), with carboplatin showing a comparatively higher incidence. Among the platinum-based regimens, the paclitaxel–carboplatin (PC) combination exhibited the strongest association with PN (p = 0.049). The majority of PN cases were mild, with grade 3 and 4 events occurring exclusively in the carboplatin group. However, no statistically significant association was observed between treatment groups and PN severity (p > 0.05). Interpretation and conclusions: The study demonstrated a significant association between the paclitaxel-carboplatin (PC) regimen and the incidence of peripheral neuropathy (PN), especially in ovarian and endometrial cancers, suggesting a possible additive neurotoxic effect of paclitaxel and carboplatin in combination. These findings highlight the need for tailored neuroprotective strategies at the initiation of treatment, especially when the PC regimen is prescribed.
Keywords: Paclitaxel-carboplatin, Paclitaxel-carboplatin induced peripheral neuropathy, Peripheral neuropathy, Platinum-induced peripheral neuropathy, PIPN.
Keywords:
Paclitaxel-carboplatin, Paclitaxel-carboplatin induced peripheral neuropathy, Peripheral neuropathy, Platinum-induced peripheral neuropathy, PIPNDOI
https://doi.org/10.22270/jddt.v16i9.7953References
1. Sathishkumar K, Chaturvedi M, Das P, Stephen S, Mathur P. Cancer incidence estimates for 2022 & projection for 2025: Result from National Cancer Registry Programme, India. Indian J Med Res. 2022 Oct-Nov;156(4&5):598-607. PMCid:PMC10231735 https://doi.org/10.4103/ijmr.ijmr_1821_22 PMid:36510887
2. Behranvand N, Nasri F, Zolfaghari Emameh R, et al. Chemotherapy: a double-edged sword in cancer treatment. Cancer immunology, immunotherapy. 2022 Mar;71(3):507-26. https://doi.org/10.1007/s00262-021-03013-3 PMid:34355266
3. Bae EH, Greenwald MK, Schwartz AG. Chemotherapy-induced peripheral neuropathy: mechanisms and therapeutic avenues. Neurotherapeutics. 2021 Oct 1;18(4):2384-96. https://doi.org/10.1007/s13311-021-01142-2 PMid:34676514 PMCid:PMC8804039
4. Burgess J, Ferdousi M, Gosal D, et al. Chemotherapy-induced peripheral neuropathy: epidemiology, pathomechanisms and treatment. Oncology and therapy. 2021 Dec 1:1-66.
5. Starobova H, Vetter I. Pathophysiology of chemotherapy-induced peripheral neuropathy. Frontiers in molecular neuroscience. 2017 May 31;10:174. https://doi.org/10.3389/fnmol.2017.00174 PMid:28620280
6. Brozou V, Vadalouca A, Zis P. Pain in platin-induced neuropathies: a systematic review and meta-analysis. Pain and Therapy. 2018 Jun;7:105-19. https://doi.org/10.1007/s40122-017-0092-3 PMid:29196945 PMCid:PMC5993684
7. Calls A, Carozzi V, Navarro X, Monza L, Bruna J. Pathogenesis of platinum-induced peripheral neurotoxicity: Insights from preclinical studies. Experimental Neurology. 2020 Mar 1;325:113141. https://doi.org/10.1016/j.expneurol.2019.113141 PMid:31865195
8. Hu X, Jiang Z, Teng L, Yang H, Hong D, Zheng D, Zhao Q. Platinum-induced peripheral neuropathy (PIPN): ROS-related mechanism, therapeutic agents, and nanosystems. Frontiers in Molecular Biosciences. 2021 Nov 24;8:770808. https://doi.org/10.3389/fmolb.2021.770808 PMid:34901160 PMCid:PMC8652200
9. Song SJ, Min J, Suh SY, et al. Incidence of taxane-induced peripheral neuropathy receiving treatment and prescription patterns in patients with breast cancer. Support Care Cancer. 2017 Jul;25(7):2241-2248. https://doi.org/10.1007/s00520-017-3631-x PMid:28204996
10. Pourghasemian M, Mehr AD, Molaei M, Habibzadeh A. Outcome of FOLFOX and modified DCF chemotherapy regimen in patients with advanced gastric adenocarcinoma. Asian Pacific Journal of Cancer Prevention: APJCP. 2020 Aug;21(8):2337. https://doi.org/10.31557/APJCP.2020.21.8.2337 PMid:32856863 PMCid:PMC7771915
11. Mohammed S, Othieno-Abinya NA, Amayo E, et al. Prevalence and predictors of Cisplatin-induced peripheral neuropathy at the kenyatta national hospital. Journal of global oncology. 2019 Sep;5:1-6. https://doi.org/10.1200/JGO.19.00097 PMid:31479343 PMCid:PMC6733204
12. Shah A, Hoffman EM, Mauermann ML, Loprinzi CL, Windebank AJ, Klein CJ, Staff NP. Incidence and disease burden of chemotherapy-induced peripheral neuropathy in a population-based cohort. Journal of Neurology, Neurosurgery & Psychiatry. 2018 Jun 1;89(6):636-41. https://doi.org/10.1136/jnnp-2017-317215 PMid:29439162 PMCid:PMC5970026
13. Feng G, Zhou X, Chen J, Li D, Chen L. Platinum drugs-related safety profile: the latest five-year analysis from FDA adverse event reporting system data. Frontiers in oncology. 2023 Jan 11;12:1012093. https://doi.org/10.3389/fonc.2022.1012093 PMid:36713566 PMCid:PMC9875054
14. Sun S, Tang L, Zhang J, et al. Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer. International journal of nanomedicine. 2014 Mar 19:1443-52. https://doi.org/10.2147/IJN.S58275 PMid:24672237 PMCid:PMC3964033
15. Guastalla JP, Pujade-Lauraine E, Weber B, Cure H, Orfeuvre H, Mousseau M, Vincent P, Dieras V, Tubiana-Mathieu N, Jacquin JP, Mignot L. Efficacy and safety of the paclitaxel and carboplatin combination in patients with previously treated advanced ovarian carcinoma: a multicenter GINECO (Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens) phase II study. Annals of oncology. 1998 Jan 1;9(1):37-43. https://doi.org/10.1023/A:1008211909585 PMid:9541681
16. Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Neurotoxicity associated with a regimen of carboplatin (AUC 5-6) and paclitaxel (175 mg/m2 over 3 h) employed in the treatment of gynecologic malignancies. Journal of cancer research and clinical oncology. 2001 Jan;127(1):55-8. PMCid:PMC12165049 https://doi.org/10.1007/s004320000157 PMid:11206272
17. Kalidindi AV, Dubashi B, Jayanthi M, Shewade DG. Efficacy and safety of capecitabine and oxaliplatin (CAPOX) treatment in colorectal cancer: An observational study from a tertiary cancer center in South India. Indian Journal of Cancer. 2022 Jan 1;59(1):73-9. https://doi.org/10.4103/ijc.IJC_618_19 PMid:33402602
Published
Abstract Display: 0 
PDF Downloads: 0 PDF Downloads: 0 How to Cite
Issue
Section
Copyright (c) 2026 R Bhavadharani , V G Sapthami Ramya , K Bhavadharini , Shailaja Krishnamoorthy , M P Ram Prabu , C Emmanuel
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.